223 related articles for article (PubMed ID: 20536296)
21. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report.
Lin LC; Lai PC; Yang SF; Yang RC
Kaohsiung J Med Sci; 2009 Feb; 25(2):82-6. PubMed ID: 19321411
[TBL] [Abstract][Full Text] [Related]
22. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
Kim SH; Kim M; Lee KW; Kim SH; Kang HR; Park HW; Jee YK
Pharmacogenomics; 2010 Jun; 11(6):879-84. PubMed ID: 20504258
[TBL] [Abstract][Full Text] [Related]
23. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI
Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
[TBL] [Abstract][Full Text] [Related]
24. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Morel E; Escamochero S; Cabañas R; Díaz R; Fiandor A; Bellón T
J Allergy Clin Immunol; 2010 Mar; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
[TBL] [Abstract][Full Text] [Related]
25. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
26. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
[TBL] [Abstract][Full Text] [Related]
27. Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
Knowles S; Shear NH
Dermatol Ther; 2009; 22(5):441-51. PubMed ID: 19845721
[TBL] [Abstract][Full Text] [Related]
28. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
Murata J; Abe R; Shimizu H
J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
[TBL] [Abstract][Full Text] [Related]
29. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.
Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
Br J Dermatol; 2006 Oct; 155(4):722-8. PubMed ID: 16965421
[TBL] [Abstract][Full Text] [Related]
30. Severe cutaneous adverse reactions to drugs.
Chia FL; Leong KP
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
[TBL] [Abstract][Full Text] [Related]
31. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
32. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hung CC; Liu WC; Kuo MC; Lee CH; Hwang SJ; Chen HC
Am J Nephrol; 2009; 29(6):633-8. PubMed ID: 19155617
[TBL] [Abstract][Full Text] [Related]
33. The genetics of antiepileptic drug-induced skin reactions.
Hakimian S; Miller JW
Clin Pharmacol Ther; 2011 Jun; 89(6):908-10. PubMed ID: 21451507
[No Abstract] [Full Text] [Related]
34. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
35. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
[TBL] [Abstract][Full Text] [Related]
36. Association of combined IL-13/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications.
Ueta M; Sotozono C; Inatomi T; Kojima K; Hamuro J; Kinoshita S
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1809-13. PubMed ID: 18263811
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide association study of serious blistering skin rash caused by drugs.
Shen Y; Nicoletti P; Floratos A; Pirmohamed M; Molokhia M; Geppetti P; Benemei S; Giomi B; Schena D; Vultaggio A; Stern R; Daly MJ; John S; Nelson MR; Pe'er I;
Pharmacogenomics J; 2012 Apr; 12(2):96-104. PubMed ID: 21221126
[TBL] [Abstract][Full Text] [Related]
38. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
39. Expression of α-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions.
Morel E; Alvarez L; Cabañas R; Fiandor A; Díaz R; Escamochero S; Prior N; Blanca M; Bellón T
Allergy; 2011 Mar; 66(3):360-7. PubMed ID: 20880148
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of drug hypersensitivity.
Phillips EJ; Mallal SA
Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
